Skip to main content
ENDO 2026 Main banner

Diabetes and Vascular Disease

MTP17 - GLP-1 Agonists and Pancreatitis/Pancreatic Lesions: What Is the Evidence and When Are They Contraindicated?

Sunday, June 14, 2026
1:45 PM - 2:25 PM CT
Location: Room W375A

    Meet the Professor Speaker(s)

  • Pankaj Shah, MD

    MAYO CLINIC
    Rochester, MN, United States

Disclosure(s):
Pankaj Shah, MD: No financial relationships to disclose

Learning Objectives:

  • Stop measuring pancreatic enzymes as a precaution for people receiving GLP-1 receptor agonists (GLP-1 RAs).
  • Use GLP-1 RAs in people with a history of pancreatitis from other causes.
  • Use GLP-1 RAs in people with pancreatic lesions, with an understanding of the uncertainty regarding the effect of these medications on the risk of pancreatic cancer in individuals at high risk.